Myeloma Trial, Recruiting NCT06789003 Sponsor: Centre Hospitalier Henri Duffaut - Avignon Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT06789003
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older
  • People diagnosed with chronic myeloid leukaemia (CML) in the chronic phase, where oral (tablet-based) treatment is an option
  • People who have been diagnosed with multiple myeloma
  • People for whom a stem cell transplant using their own stem cells (autologous) is considered a suitable option by their doctor
  • People who are able to read, understand, and fill in a questionnaire written in French
  • People with a general health/activity level rated at 2 or below on the WHO performance scale (confirm with trial site)
  • People enrolled in the French social security system
  • People who have been given a medical prescription for adapted physical activity (APA) by their doctor

Who may not be able to join:

  • People who have had another cancer diagnosis within the past 3 years (certain exceptions may apply, such as some skin cancers, previously removed localised cancers, or stable breast or prostate cancers being managed with hormone therapy — confirm with trial site)
  • People who have a medical reason that makes adapted physical activity (APA) unsuitable for them, such as heart failure, chest pain (angina), poorly controlled high blood pressure, bone metastases, or severe bone loss (osteoporosis)
  • People who have nerve problems affecting their sensation or movement (such as numbness, weakness, or coordination difficulties)
  • People who are in legal custody or under a form of legal guardianship or protection
  • People who are considered by the medical team to be socially or psychologically unsuitable for participation in a research study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: (+33)432759392

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Henri Duffaut - Avignon
Registry
ClinicalTrials.gov
Start date
10 February 2025
Est. completion
28 February 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

1. Evaluate the effect of the APA program on fatigue status.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov